Article Listing - Winston Pharma gets orphan status for civamide
SELF-MEDICATION IN EUROPE IN THE 1990s
23 March 1992
The criteria for success for companies marketing self-medication pharmaceutical products in Europe will change fundamentally over the next three years,...
PIERRE FABRE ON EXPANSION TRAIL
23 March 1992
The second largest independent French drugs group, Pierre Fabre, is to give priority to research and development in order to...
UK MARKETING OF MAXEPA
23 March 1992
The only prescription formulation of the fish oil-derived omega-3 fatty acid product Maxepa is to be marketed in the UK...
GENETIC IMMUNIZATION ADVANCE
23 March 1992
The new technique of genetic immunization could represent a time- and labor-saving means of eliciting antibodies and it could offer...
CUROSURF LICENSING DEAL
23 March 1992
Switzerland's Ares-Serono Group and Parma, Italy-based Chiesi Farma-ceutici have announced an agreement in which the former acquires exclusive rights to...
FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM
23 March 1992
The task of pharmaceutical industry management is to achieve the best possible balance between the constant pull of the...
ARGENTINE GENERICS POLICY CHANGE
23 March 1992
Having established at the beginning of 1992 a generics policy which required doctors to prescribe medicines using generic names only,...
WORLD NEWS IN BRIEF
23 March 1992
- In China, the State Statistical Bureau reports that prices of medicines and medical products in 1991 were 3.4% higher...
US FDA "SHOULD BAN SPEAKER LISTS"
23 March 1992
Among the views presented to the US Food and Drug Administra-tion on its proposed draft guideline on Drug Company-Sponsored Activities...
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
Prescription prices in the USA increased by 8.1% last year to an average of $14.75 at pharmacy acquisition prices, compared...
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
